Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Synapse ; 74(3): e22139, 2020 03.
Article in English | MEDLINE | ID: mdl-31610050

ABSTRACT

CB2 receptors (CB2 R) are expressed in midbrain neurons. To evidence the control of dopamine release in dorsal striatum by CB2 R, we performed experiments of [3 H]-dopamine release in dorsal striatal slices. We found a paradoxical increase in K+ -induced [3 H]-dopamine release by CB2 R activation with GW 833972A and JWH 133 two selective agonist. To understand the mechanism involved, we tested for a role of the D2 autoreceptor in this effect; because in pallidal structures, the inhibitory effect of CB1 receptors (CB1 R) on GABA release is switched to a stimulatory effect by D2 receptors (D2 R). We found that the blockade of D2 autoreceptors with sulpiride prevented the stimulatory effect of CB2 R activation; in fact, under this condition, CB2 R decreased dopamine release, indicating the role of the D2 autoreceptor in the paradoxical increase. We also found that the effect occurs in nigrostriatal terminals, since lesions with 6-OH dopamine in the middle forebrain bundle prevented CB2 R effects on release. In addition, D2 -CB2 R interaction promoted cAMP accumulation, and the increase in [3 H]-dopamine release was prevented by PKA blockade. D2 -CB2 R coprecipitation and proximity ligation assay studies indicated a close interaction of receptors that could participate in the observed effects. Finally, intrastriatal injection of CB2 R agonist induced contralateral turning in amphetamine-treated rats, which was prevented by sulpiride, indicating the role of the interaction in motor behavior. Thus, these data indicate that the D2 autoreceptor switches, from inhibitory to stimulatory, the CB2 R effects on dopamine release, involving the cAMP â†’ PKA pathway in nigrostriatal terminals.


Subject(s)
Corpus Striatum/metabolism , Dopamine/metabolism , Receptor, Cannabinoid, CB2/metabolism , Receptors, Dopamine D2/metabolism , Substantia Nigra/metabolism , Amphetamine/pharmacology , Animals , Cannabinoid Receptor Agonists/pharmacology , Cannabinoids/pharmacology , Cells, Cultured , Corpus Striatum/cytology , Corpus Striatum/drug effects , Cyclic AMP/metabolism , Dopamine D2 Receptor Antagonists/pharmacology , Dopaminergic Neurons/drug effects , Dopaminergic Neurons/metabolism , Dopaminergic Neurons/physiology , Male , Movement , Presynaptic Terminals/drug effects , Presynaptic Terminals/metabolism , Presynaptic Terminals/physiology , Pyridines/pharmacology , Pyrimidines/pharmacology , Rats , Rats, Wistar , Receptor, Cannabinoid, CB2/agonists , Substantia Nigra/cytology , Substantia Nigra/drug effects , Sulpiride/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL